Don't invest unless you're prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more
|
|
|
|
|
|
There is a frequent, difficult moment when a child’s behaviour stops making sense and the parents or teachers around them simply don’t know what to do. While 1 in 10 children think, learn, and process the world differently, the adults shaping their daily environments are often left without the clear, immediate tools needed to respond effectively.
Oli help was created to fill this structural gap. It provides an AI-powered, private, and evidence-based companion that doesn't replace healthcare, but complements it, extending clinical-grade support directly into the home and classroom.
Explore the campaign below and back the AI companion re-shaping neuro-inclusive care. 👇
|
|
🚀 TRACTION & KEY ACCOMPLISHMENTS
Since launching its initial rollout in Italy, the platform has surpassed 10,000+ downloads from parents and maintains an average of 3.8 weekly sessions per active user.
Strong commercial indicators: The app demonstrated a 20%+ conversion rate to paid membership pre-freemium, stabilizing efficiently above 7% conversion post-freemium.
B2B classroom scalability: Expanded its footprint into the education sector, with 180+ educators actively using the dedicated teacher beta to implement neuroinclusive strategies.
Clinical validation: Oli help has already successfully completed its first UK clinical study in collaboration with the University of Southampton, yielding highly positive early results.
|
|
🌏 MARKET OPPORTUNITY
Moving Beyond a Single Diagnosis: While starting with a core focus on ADHD, Oli help recognises that most neurodivergent children have complex, overlapping needs (including autism, dyslexia, dyspraxia, and language disorders) that rarely fit into a neat diagnostic category.
Empowering the Caregiver Circle: Parents, teachers, and caregivers heavily shape a child's day-to-day environment, yet they are routinely left without the practical, real-time tools required to respond consistently and effectively.
Overcoming Systemic Bottlenecks: Existing public and private healthcare support networks suffer from severe structural limitations, leaving families facing immense backlogs and a lack of continuous, daily care.
A Generational Opportunity: This combination of rising awareness and strained traditional systems has created a massive structural gap, positioning Oli help to lead a vital new category of transdiagnostic digital health.
|
|
|
Funds will be allocated across three key areas:
-
UK expansion: Launch and scale in the UK market, building on early clinical validation and local partnerships
- Advanced AI personalisation: Further develop their AI companion to deliver more precise, context-aware and adaptive guidance, moving towards fully transdiagnostic support.
- Clinical validation & reimbursement pathway: Advance their clinical programme, including RCT readiness, to support integration into healthcare systems and unlock reimbursement.
|
|
|
|
|
Investing involves risks, including the risk of partial or entire loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Your investment is not covered by a deposit guarantee scheme or by an investor compensation and scheme. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future. Republic Europe does not make investment recommendations to you and any investment decision should be made on the basis of the full campaign. No communications from Republic Europe, through email or any other medium, should be construed as an investment recommendation.
|
|
|
This financial promotion and marketing communication has been approved by Seedrs Limited, authorised and regulated by the Financial Conduct Authority and Seedrs Europe Limited regulated by the Central Bank of Ireland both trading as Republic Europe, on 8 May 2026.
© Seedrs Limited 2026. All rights reserved. Republic Europe is a registered European Community trademark (No. 008771537), registered United Kingdom trademark (No. UK00908771537) and registered United States service mark (No. 85423072). Seedrs Europe Limited is a private company limited by shares registered in Ireland (No. 699574), with registered office at 42, Pearse Street, Dublin 2, D02 YX88, Ireland. Seedrs Limited is a limited company registered in England and Wales (No. 06848016), with registered office at Cubo Soho, Ilona Rose House, Manette Street, London W1D 4AL, United Kingdom, VAT No. GB 208 3065 32.
europe.republic.com is a website owned and operated by Seedrs Europe Limited and/or Seedrs Limited (each trading as Republic Europe).
This message and any attachments are confidential, and may be protected by legal privilege. Nothing in this message shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind, and nothing in this email constitutes such advice. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe or its affiliates, you should consult a professional adviser.
Don't want to receive any Featured Campaign Updates? Unsubscribe here. To manage your Republic Europe marketing communications please visit your preferences centre.
|
|
|
|
